News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III (World)
NovoCure Release: Combination Of Optune With Temozolomide Demonstrates Unprecedented Five-Year Survival For Newly Diagnosed Glioblastoma Patients 9/25/2017
Shionogi Announces Results For Lusutrombopag (S-888711) Phase III Study (L-PLUS2) For The Treatment Of Thrombocytopenia In Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures 9/25/2017
Sinovac Biotech Ltd. (SVA) Reports Preliminary Top-Line Results From Phase III Clinical Trial For Varicella Vaccine Candidate Against Chickenpox 9/25/2017
AstraZeneca PLC (AZN)'s COPD Drug Bevespi Aerosphere Scores a Phase III Win 9/25/2017
3 Biotechs With Make-or-Break Trial Results, FDA Meetings Coming Soon 9/22/2017
GENFIT (ALGFT): Risk Of Confusion Between PPAR Alpha/Delta Phase III Drug Candidate Elafibranor And PPAR A/D/Gamma Phase II Compound Lanifibranor 9/21/2017
Akari to Push Lead Drug Into Phase III For PNH In Q1 2018, Stock Surges 9/21/2017
Theravance Biopharma (TBPH) Highlights Positive Headline Results From IMPACT Study Of Trelegy Ellipta Announced By GlaxoSmithKline (GSK) And Innoviva Inc. (THRX) 9/21/2017
Shire (SHPG), Shionogi's Adult ADHD Drug Hits Phase III Goals 9/20/2017
Nabriva (NBRV)'s Stock Explodes as Pneumonia Drug Wows in Two Phase III Trials 9/19/2017
PHARNEXT Amends The Protocol Of The International Pivotal Phase III Trials Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 9/19/2017
Theravance Biopharma (TBPH) Highlights GlaxoSmithKline (GSK) And Innovia's Receipt Of Positive Opinion From CHMP In Europe For Trelegy Ellipta (Closed Triple) 9/18/2017
Pluristem Therapeutics (PSTI) Surges After Lead Drug Is Granted Fast Track Status 9/18/2017
Novartis AG (NVS)' Xolair Confirms Re-Treatment Efficacy In Chronic Spontaneous Urticaria Patients After Treatment Interruption 9/18/2017
Saniona Reports Encouraging Start For Tesofensine Phase III Study 9/18/2017
Bavarian Nordic (BAVA.CO) Plummets 49% After Cancer Vaccine Flunks Late-Stage Test 9/15/2017
Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic In Terms Of Efficacy And Safety In Long-Term Study 9/14/2017
Successful Phase III Trial For ALK-Abello A/S’s Tree Allergy SLIT-Tablet 9/14/2017
SELLAS Life Sci' Galinpepimut-S Induces Specific, Robust And Durable Immune Responses In Patients With High-Risk Multiple Myeloma - Correlated With Clinical Benefit 9/14/2017
Astellas (ALPMY), Pfizer (PFE)'s Prostate Cancer Drug Hits Late-Stage Trial Goals 9/14/2017
Dermira (DERM), UCB Group (UCBJF.PK) Release: New CIMZIA (Certolizumab Pegol) Findings Presented At European Academy Of Dermatology And Venereology (EADV) Congress 9/14/2017
Novartis AG (NVS) Posts Stunning 5-Year Sustained Late-Stage Psoriasis Data 9/13/2017
AIT Therapeutics’ Adjuvant Nitric Oxide Treatment Shown To Be Safe And Effective In The Compassionate Use Setting In Cystic Fibrosis Patients With Non-Tuberculous Mycobacteria (NTM) Infection 9/13/2017
Sanofi (SNY) and Zealand Pharma  (ZEAL.CO) Release: Soliqua 100/33 Provided Earlier Blood Sugar Control Than Insulin Glargine 100 Units/Ml 9/13/2017
Shionogi Release: S-033188 Phase III CAPSTONE-1 Study Results For Treatment Of Influenza Presented At The European Scientific Working Group On Influenza Conference 9/13/2017
Novo Nordisk A/S (NVO) Release: Fiasp Significantly Improved Overall Blood Sugar Control In Type 1 Diabetes Long-Term 9/12/2017
Advicenne Announces Positive Pivotal Phase III Clinical Data For ADV7103 In Adults And Children Suffering From Distal Renal Tubular Acidosis (dRTA) 9/12/2017
Amgen (AMGN) Release: EVENITY (romosozumab) ARCH Study Results Published In The New England Journal of Medicine 9/12/2017
GlaxoSmithKline (GSK) Eyes Regulatory Filings With Mixed Phase III COPD Data 9/12/2017
Onxeo (ONXEO.PA) Plunges After Liver Cancer Drug Fails Late-Stage Study 9/12/2017
Investors are Antsy After Roche (RHHBY) Suffers Another Late-Stage Trial Flop 9/11/2017
AstraZeneca PLC (AZN) Restores Cancer Drug Hopes With Impressive Lung Cancer Data 9/11/2017
Amgen (AMGN) And Allergan (AGN) Present Phase III Data On Biosimilar Trastuzumab Candidate ABP 980 At The European Society For Medical Oncology 2017 Congress 9/11/2017
Advicenne Announces Positive Pivotal Phase III Clinical Data For ADV7103 In Adults And Children Suffering From Distal Renal Tubular Acidosis (dRTA) 9/11/2017
Teva (TEVA) Showcases Data Demonstrating Potential Of Fremanezumab To Address Significant Unmet Need In Patients With Chronic And Episodic Migraine 9/11/2017
Regeneron (REGN) And Sanofi (SNY) Announce Positive Dupilumab Topline Results From Phase III Trial In Uncontrolled Persistent Asthma 9/11/2017
Seqirus Release: New Phase III Study Shows Significantly Greater Efficacy In Children 6-24 Months Who Receive Adjuvanted Influenza Vaccine (Aqiv) 9/11/2017
Novartis AG (NVS) Phase III Study Demonstrates Adjuvant Tafinlar + Mekinist Reduced The Risk Of Disease Recurrence By 53% In Patients With Resected BRAF V600 Mutation-Positive Melanoma 9/11/2017
Janssen-Cilag International NV (JNJ) Release: New Data Presented At ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits In Patient Reported Outcomes In Both Metastatic Hormone-Sensitive And Castration-Resistant Prostate Cancer 9/8/2017
ObsEva (OBSV) Announces The Completion Of Patient Recruitment In The IMPLANT2 Phase III Clinical Trial In Assisted Reproductive Technology Ahead Of Schedule 9/6/2017
PHARNEXT Announces That The DSMB Recommends Continuing The Ongoing Phase III Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A 9/6/2017
Oramed (ORMP) Announces Successful Meeting With FDA For Oral Insulin 9/5/2017
Pluristem Therapeutics (PSTI) Release: $8.7 Million Awarded To Support Phase III Femoral Neck Fracture Trial By EU Horizon 2020 Program 9/5/2017
Novartis AG (NVS) Landmark Phase III Trial Shows Fingolimod Significantly Reduces Relapses In Children And Adolescents With MS 9/5/2017
Themis Release: Chikungunya Vaccine Development Towards Phase III Trials Boosted By Innovate UK 9/5/2017
Investors Wait with Bated Breath for AstraZeneca PLC (AZN)'s Cancer Trial Data Next Week 9/1/2017
UroGen Receives FDA Fast Track Designation For Mitogel For The Treatment Of Upper Tract Urothelial Carcinoma (UTUC) 8/29/2017
A First: Novartis AG (NVS) Drug May Prevent Heart Attacks and Cut Lung Cancer Risk Too 8/29/2017
Bayer (BAY) Release: COMPASS Study Presented At ESC Congress 2017 – Largest Rivaroxaban Study To Date, Enrolled 27,395 Patients To Investigate CAD And PAD 8/28/2017
Novartis AG (NVS) Announces Analysis Published In The Lancet Showing ACZ885 Reduced Lung Cancer Mortality By 77% In The CANTOS Study With Further Studies Planned 8/28/2017
The FDA Calls Kyowa Hakko's Lymphoma Drug a Breakthrough 8/25/2017
Genmab A/S (GEN.CO) Announces Positive Topline Results In Phase III ALCYONE Study Of Daratumumab In Front Line Multiple Myeloma 8/24/2017
Octapharma AG Release: Publication Of Clinical Data Demonstrating Low Immunogenicity And Excellent Efficacy Of Nuwiq In Previously Untreated Patients 8/23/2017
Boehringer Ingelheim: Advancing Anticoagulation Care With New Data At ESC Congress 2017 8/21/2017
Mithra Pharmaceuticals Announces First Subject Completes Estelle Phase III Study 8/18/2017
New Data Shows Previously Allergic Children Still Able To Tolerate Peanut Four Years After Treatment With A Novel Immunotherapy Licensed By Prota Therapeutics 8/17/2017
Novo Nordisk A/S (NVO)’s Diabetes Drug Beats Out Eli Lilly (LLY)’s Trulicity in Phase III Trials 8/17/2017
Can-Fite BioPharma (CFBI) Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson 8/7/2017
Starpharma Shares Jumped on Phase III Results of Vivagel 8/7/2017
Biofrontera AG Agrees With U.S. FDA On Ameluz Development Plan To Treat Basal Cell Carcinoma 8/4/2017
Korea's ViroMed Starts Trial Of Gene Therapy For Diabetic Foot Ulcers 8/4/2017
Roche (RHHBY)’s Tecentriq Hits Trouble with NICE in Bladder Cancer 8/3/2017
Foamix Pharma (FOMX) Announces Dosing Of First Patient In Third Phase III Acne Study For Minocycline Foam FMX101 8/3/2017
Hutchison China MediTech (Chi-Med)'s Innovative Drug Portfolio: Eight Candidates In 31 Trials 8/3/2017
FDA Calls AstraZeneca PLC (AZN) and MedImmune (AZN)’s Imfinzi a Breakthrough 8/2/2017
DBV Tech Initiates Phase III Study Of Viaskin Peanut In Peanut-Allergic Patients One To Three Years Of Age 8/2/2017
Sandoz Canada Release: Sandoz Erelzi (Etanercept) Receives Positive Reimbursement Recommendation From Common Drug Review For Treatment Of Multiple Inflammatory Diseases 8/2/2017
GenSight Completes Enrollment Of RESCUE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy 8/1/2017
Kitov (KTOV) Submits New Drug Application To FDA For KIT-302 8/1/2017
Why AstraZeneca PLC (AZN)'s MYSTIC Trial Failure May be a Bad Sign for Bristol-Myers Squibb (BMY) 7/31/2017
RedHill Biopharma (RDHL) Announces Unanimous Positive DSMB Recommendation For Continuation Of The Phase III Study With RHB-104 For Crohn’s Disease 7/31/2017
AstraZeneca PLC (AZN) Seals a $8.5 Billion R&D Cancer Tie-Up With Merck & Co. (MRK) 7/28/2017
AstraZeneca PLC (AZN) Loses $10 Billion in Value as Long-Awaited MYSTIC Trial Disappoints 7/28/2017
Galderma Announces Enrollment Of First Patient In Phase IIb Nemolizumab Trial In Atopic Dermatitis 7/28/2017
Dr. Reddy's Laboratories Ltd. (RDY)’s And CHD Bioscience Announce Global License And Commercialization Agreement For Phase III Clinical Trial Candidate For Mitigation Of Surgical Site Infections 7/27/2017
Merck & Co. (MRK) Plans to File NDA for HIV Treatment Doravirine Based on Phase III Results 7/26/2017
Resverlogix (RVX.TO) Receives Approval Pathway From The FDA As To The Inclusion Of USA Patients In The Phase III BETonMACE Trial 7/25/2017
Neuronix Ltd. Announces The First Group Of Mild To Moderate Alzheimer Patients To Be Successfully Treated By The Neuroad Therapy System In London 7/25/2017
Janssen-Cilag International NV (JNJ) Announces Phase III Pivotal Study Results for Darunavir-Based Complete Treatment Regimen 7/25/2017
Shionogi Announces Positive Top-Line Results For S-033188 Phase III Study (CAPSTONE-1) In Otherwise Healthy Influenza Patients 7/24/2017
Uncertainty Hits as Roche (RHHBY) is Dealt Multiple Clinical Trial Setbacks 7/21/2017
Lexicon Pharma (LXRX) Collaborator Ipsen (IPN.PA) Receives Positive CHMP Opinion For Xermelo (Telotristat Ethyl) 7/21/2017
SillaJen And Lee's Pharmaceutical Announce Approval By The China CFDA To Commence Phase III Clinical Trial For Oncolytic Immunotherapy, Pexa-Vec, In Liver Cancer 7/21/2017
BrainStorm Cell Awarded $16 Million Non-Dilutive Grant From CIRM In Support Of Phase III Clinical Trial Of NurOwn In ALS 7/21/2017
Samsung Bioepis Emerging as a Strong Player in the Autoimmune Space 7/20/2017
Theravance Biopharma (TBPH) AndMylan (MYL) Announce Positive Results From 12-Month Phase III Safety Study Of Revefenacin (TD-4208) In Patients With Chronic Obstructive Pulmonary Disease (COPD) 7/20/2017
Kamada (KMDA) Submits Proposed Phase III Protocol To FDA For Inhaled Alpha-1 Antitrypsin For Treatment Of Alpha-1 Antitrypsin Deficiency Disease 7/20/2017
Genentech (RHHBY) R&D Exec Reveals Alzheimer's is Still A Priority 7/19/2017
How Much Money Will These 5 Pharma Companies' Pipelines Generate in 5 Years 7/19/2017
In Alzheimer's, The 'Juggernaut Is Changing Course,' Says TauRx Pharma Chief Exec 7/18/2017
DelMar Pharma Announces Completion Of First Site Initiation Visit For STAR-3 Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 7/18/2017
Horizon Pharma (HZNP) Announces Four Poster Presentations On PROCYSBI (Cysteamine Bitartrate) Delayed-Release Capsules At Cystinosis Research Network 2017 Family Conference 7/14/2017
Bio Products Laboratory Presents New Phase III Data Demonstrating Prophylactic Coagadex (Coagulation Factor X, Human) Dosing Prevents Or Reduces Bleeding Episodes In Children With Moderate To Severe Hereditary Factor X Deficiency 7/12/2017
CSL Behring Release: New Data Demonstrate Prophylactic Treatment With IDELVION Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B 7/12/2017
RedHill Biopharma (RDHL) Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn’s Disease 7/12/2017
Vifor Pharma Announces Three Outcomes Trials In Heart Failure And Iron Deficiency 7/12/2017
Boehringer Ingelheim Release: Final Phase III Study Results Confirm Benefit Of Praxbind As Reversal Agent For Pradaxa Patients In Emergency Situations 7/11/2017
ProMetic Life Sci (PFSCF.PK) Announces Positive Long Term Clinical Data On Ryplazym In Plasminogen Congenital Deficiency And Provides Regulatory Update 7/11/2017
Oramed (ORMP) Announces End-Of-Phase II Meeting With FDA To Initiate Phase III Program 7/11/2017
Teva (TEVA) And The Huntington Study Group Announce Publication Of Data For AUSTEDO (Deutetrabenazine) Tablets In Huntington Disease From ARC-HD Study In JAMA Neurology 7/11/2017
Chugai Pharma's Bispecific Antibody "Emicizumab" Global Phase III Data In Patients With Haemophilia A With Inhibitors Published In The New England Journal of Medicine Online 7/10/2017
Resverlogix (RVX.TO) Randomizes First Patient In Taiwan/China Portion Of The Phase III BETonMACE Clinical Trial 7/10/2017
Allergan (AGN) Reports New Data Reinforcing The Effectiveness Of Viberzi (Eluxadoline) To Treat The Symptoms Associated With Irritable Bowel Syndrome With Diarrhea (IBS-D), Abdominal Pain And Diarrhea 7/10/2017
Pluristem Therapeutics (PSTI) Advances Its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation At 40 Active Sites By The End Of 2017 7/10/2017
AC Immune SA Provides Seven Updates On Its Pipeline And Technology At The Alzheimer's Association International Conference 7/10/2017
Prima Biomed (PRR.AX) Announces Approval For The Initiation Of The ‘INSIGHT’ Clinical Trial 7/10/2017
Bay Area's Coherus Dealt Another Blow as Daiichi Sankyo Discontinues Work on RA Drug 7/6/2017
Worldwide Clinical Trials Selected By BrainStorm Cell As CRO For Phase III NurOwn Trial In ALS 7/5/2017
Biogen (BIIB)'s SPINRAZA (nusinersen) Receives Notice Of Compliance From Health Canada For The Treatment Of 5q Spinal Muscular Atrophy (SMA) 7/5/2017
Auris Med (EARS) Completes Enrollment Of Phase III Healos Trial Of Am-111 For The Treatment Of Sudden Deafness 7/5/2017
Bionomics Limited (BNO.AX): A Company With Deals On The Horizon 7/5/2017
Advicenne Receives Orphan Drug Designation From The EU For ADV7103 For The Treatment Of Distal Renal Tubulopathy 7/5/2017
Alkermes (ALKS) Slips As Weight Gain Concerns Sully Late-Stage Schizophrenia Data 6/30/2017
Hutchison China MediTech (Chi-Med) And AstraZeneca PLC (AZN) Initiate SAVOIR, A Global Phase III Trial Of Savolitinib In Papillary Renal Cell Carcinoma 6/29/2017
Can Merck & Co. (MRK) And Novartis AG (NVS)'s Surprise Heart Drug Success Translate To Blockbuster Sales? 6/29/2017
Teva (TEVA) Announces Publication Of AIM-TD Study Results In The Lancet Psychiatry For The Investigational Use Of Deutetrabenazine In Tardive Dyskinesia 6/29/2017
Resverlogix (RVX.TO) Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase III Study Of Apabetalone 6/28/2017
Investors Take Options Cover Ahead Of AstraZeneca PLC (AZN)'s Much-Anticipated Cancer Trial Data 6/28/2017
NovoCure To Present Three Abstracts On Tumor Treating Fields And Pancreatic Cancer At The European Society For Medical Oncology 19th World Congress On Gastrointestinal Cancer 6/28/2017
Kitov (KTOV) Updates On KIT-302 New Drug Application 6/27/2017
Teva (TEVA), Xenon Pharma's Nerve Pain Med Fails To Meet All Endpoints In Phase III Study 6/27/2017
Investors Relieved as Seattle Genetics (SGEN) Pulls Out Win for Phase III Lymphoma Trial 6/27/2017
European Hematology Association: Early Metabolic Response Determination By FDG-PET Allows Substantial Reduction Of Chemotherapy And Its Toxicity In Patients With Advanced Stage Hodgkin Lymphoma: The GHSG HD18 Study 6/26/2017
Mithra Pharmaceuticals Release: Estelle Phase IIb Results On Well-Being And Body Weight Published In Leading Peer-Reviewed Journal 6/26/2017
OSE Immunotherapeutics Announces Temporary Pause Of Patient Accrual While Continuing Treatment For Patients Already Enrolled In Phase III Clinical Trial Of Tedopi In Advanced Lung Cancer 6/26/2017
DelMar Pharma Receives Institutional Review Board Approval For Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 6/22/2017
Top 3 Biotechs With Potential Blockbusters In The Late-Stage Pipeline 6/22/2017
Indivior Presents Results From The Phase III Pivotal Study Of RBP-6000 Buprenorphine Monthly Depot For The Treatment Of Opioid Use Disorder 6/22/2017
Surprise: Novartis AG (NVS) Heart Drug Wows in Late-Stage Study 6/22/2017
Advicenne To Present Preliminary Phase III Clinical Data On ADV7103 At The Upcoming European Society Of Pediatric Nephrology’s Annual Meeting 6/22/2017
Novartis AG (NVS)'s Next-Generation Eye Drug Works With Fewer Injections Than Rivals 6/21/2017
Mithra Pharmaceuticals Completes Recruitment For Additional Estelle Safety Study 6/21/2017
GlaxoSmithKline (GSK) Presents Positive Results From Phase III Revaccination Study Of Its Candidate Shingles Vaccine Shingrix At CDC's Advisory Meeting 6/21/2017
How Upcoming Mystic Data Will Be AstraZeneca PLC (AZN) CEO's Biggest Test 6/20/2017
Helsinn Group Announces Upcoming Presentation Of Phase III Data In NEPA (Netupitant/Palonestron) At MASCC/ISOO Congress In Washington DC 6/20/2017
Galapagos (GLPG.BR)' R&D Update 2017: Rapidly Advancing Our Product Candidates 6/20/2017
ASIT Biotech Discloses Comments From The Paul Ehrlich Institute And Presents Detailed Results On The Phase III Clinical Study Of Gp-ASIT + At EAACI 2017 6/19/2017
RedHill Biopharma (RDHL) To Host Conference Call On Successful Phase III Top-Line Results With BEKINDA For Acute Gastroenteritis 6/19/2017
Janssen-Cilag AG Release: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit With Single Agent Imbruvica (Ibrutinib) Vs Temsirolimus At First Relapse In Mantle Cell Lymphoma 6/19/2017
Why Drug Giants Like Merck & Co. (MRK) and AstraZeneca PLC (AZN) Scientists are Looking in the Toilet for New Cancer Treatments 6/16/2017
LEO Pharma Starts Phase III Clinical Study For Tralokinumab In Atopic Dermatitis 6/15/2017
RedHill Biopharma (RDHL) Announces Confirmatory Phase III Study Initiated With RHB-105 (TALICIA) For H. Pylori Infection 6/15/2017
RedHill Biopharma (RDHL) Announces Successful Phase III Top-Line Results With BEKINDA For Acute Gastroenteritis 6/15/2017
How Your Daily Cup Of Coffee Could Be Saving Your Liver, Journal of Hepatology Reveals 6/15/2017
Janssen Pharmaceutical Release: New Phase III Data Show Anti-TNF Alpha SIMPONI ARIA (golimumab) Significantly Improved Arthritis And Skin Manifestations In Patients With Active Psoriatic Arthritis 6/14/2017
RedHill Biopharma (RDHL) Announces Successful Phase III Top-Line Results With BEKINDA For Acute Gastroenteritis 6/14/2017
Janssen-Cilag International NV (JNJ) Release: INVOKANA (Canagliflozin) Significantly Reduces The Combined Risk Of Cardiovascular Death, Myocardial Infarction, And Stroke In The CANVAS Programme 6/13/2017
TiGenix Launches Global Phase III Trial For Cx601 6/13/2017
SoCal's Regulus (RGLS) Sinks After AstraZeneca PLC (AZN) Bails on Lead NASH Drug 6/13/2017
Foamix Pharma (FOMX) Announces Dosing Of First Patient In Phase III Rosacea Clinical Trials For FMX103 Minocycline Foam 1.5% 6/12/2017
Eli Lilly (LLY)'s Galcanezumab Significantly Reduces Number Of Migraine Headache Days For Patients With Migraine: New Results Presented At AHS 6/12/2017
Zealand Pharma  (ZEAL.CO) Release: New Analysis Shows Soliqua 100/33 Lowered HbA1c By More Than 2% In Patients With Screening Levels Greater Than 9% 6/12/2017
Novartis AG (NVS) Presents Data Demonstrating Efficacy Of AMG 334 (Erenumab) In Migraine Prevention At The American Headache Society Annual Meeting 6/9/2017
Can-Fite BioPharma (CFBI) Concludes Successful Clinical Investigator Meeting For Its Acrobat Phase III Trial Of Piclidenoson In The Treatment Of Rheumatoid Arthritis 6/8/2017
Alkermes (ALKS) Announces Initiation Of Phase III Study Of ALKS 3831 In Young Adult Patients 6/8/2017
Actelion (ALIOF.PK) Reports Good And Bad News For Phase III CDAD Trials 6/8/2017
Mallinckrodt (MNK) Enrolls First Patient In Phase III Trial Of StrataGraft Regenerative Skin Tissue 6/7/2017
Teva (TEVA)'s Fremanezumab Meets All Primary & Secondary Endpoints Across Both Monthly And Quarterly Dosing Regimens 6/7/2017
EMA Accepts Design Of NeuroDerm (NDRM)'s ND0612 Phase III Indigo Efficacy Trial 6/6/2017
Data Of Chugai Pharma's Alecensa Presented At ASCO On Global Phase III ALEX Study 6/6/2017
Janssen Pharmaceutical Announces Submissions In Europe And U.S. For Single-Tablet Regimen Of Dolutegravir Plus Rilpivirine - The First Two-Drug HIV Maintenance Treatment 6/2/2017
Novartis AG (NVS) Presents Updated Data That Reinforce The Efficacy And Safety Of Kisqali (Ribociclib) Plus Letrozole As A First-Line Option For HR+/HER2- Advanced Or Metastatic Breast Cancer 6/2/2017
Sylentis Initiates A Phase III Study For The Treatment Of Dry Eye Syndrome 6/1/2017
GENFIT (ALGFT): Positive Outcome From The 1-Year Pre-Planned Safety Review By The DSMB, In RESOLVE-IT Phase III Clinical Trial With Elafibranor 6/1/2017
Teva (TEVA) Announces Positive Results For Phase III Study Of Fremanezumab For The Prevention Of Chronic Migraine 5/31/2017
GW Pharma (GWPH) Preps For NDA As Cannabis Drug Halved Convulsions In Kids With Rare Form Of Epilepsy 5/25/2017
6 (Plus 2!) Most Notable ASCO Abstracts So Far 5/24/2017
Boehringer Ingelheim Release: American Thoracic Society 2017 Spiriva Respimat Improves Breathing For People With Asthma Regardless Of BMI Or Allergic Status 5/23/2017
Novartis AG (NVS)' New Analyses Reinforce The Potential Of Ultibro Breezhaler For COPD Patients Historically Treated With Steroids 5/23/2017
Amgen (AMGN) Faces Setback as Osteoporosis Drug is Linked to Serious Heart Side Effects 5/23/2017
Meet The New CEO Of The Dutch Biotech Making A Cure For Blood Cancer 5/22/2017
Octapharma AG Underlines Strong Commitment To Haemophilia A Patients With The Publication Of New Clinical Data On PK-Guided Personalized Prophylaxis According To The Nupreviq Approach With Nuwiq 5/22/2017
Otsuka Pharma Announces Results Of Phase III Data On Tolvaptan 5/22/2017
Nexstim Updates The Timeline For Its Supplementary E-FIT Phase III Trial In Stroke Rehabilitation 5/19/2017
Astellas (ALPMY) Announces Oncology Portfolio Updates 5/18/2017
Aurinia (AUPH) Doses First Patient In AURORA Phase III Clinical Trial Of Voclosporin In Lupus Nephritis 5/18/2017
Novartis AG (NVS) Data At ASCO, ICML And European Hematology Association Meetings Demonstrate Meaningful Advancements In Cancer Care 5/18/2017
Genmab A/S (GEN.CO) Announces Plans For New Studies Of Daratumumab 5/18/2017
Novo Nordisk A/S (NVO) Release: Early Response To Saxenda Resulted In Weight Maintenance And Additional Weight Loss Over 56 Week 5/17/2017
Promore Pharma Files Phase III Clinical Trial Application In India 5/17/2017
Can-Fite BioPharma (CFBI) Files Clinical Trial Application In Canada For Piclidenoson Ahead Of Upcoming Acrobat Rheumatoid Arthritis Phase III Study 5/16/2017
Galapagos (GLPG.BR) Release: Seven Abstracts On Filgotinib Accepted By EULAR 2017 5/16/2017
AstraZeneca PLC (AZN) Stock Hits 2017 High as Lung Cancer Med Reduces Death Risk in Phase III Study 5/15/2017
Mologen (MOLGF.PK): Recruitment Goal Achieved For The Pivotal IMPALA Study With Lefitolimod In Colorectal Cancer Patients 5/15/2017
OSE Immunotherapeutics Presents New Data On Anti-SIRPa (Effi-DEM), The Checkpoint Inhibitor Blocking Pro-Tumor And Suppressor Myeloid Cells At “Advances In Immuno-Oncology Congress,” London, May 15-16, 2017 5/15/2017
PhotoCure: Phase III Study Investigating Blue Light Flexible Cystoscopy With Cysview In Surveillance Setting Meets Primary Endpoint 5/12/2017
French Regulators Order AB Science (AB.PA) To Temporarily Suspend Work On Phase III ALS Trial 5/12/2017
4 Biotechs That Could Release Stock-Shattering Data Soon 5/11/2017
Results Of The J-ALEX Study For Chugai Pharma's Alecensa Are Published In "The Lancet" Online 5/11/2017
VBL Therapeutics (VBLX) Presents Data On VB-111 In Combination With Checkpoint Inhibitor At The 20th Annual ASGCT Meeting 5/11/2017
Orphazyme Completes Enrollment Of Patients For Phase III Clinical Trial In Niemann-Pick Type C Disease 5/11/2017
AstraZeneca PLC (AZN)'s Asthma Drug Fails to Meet Primary Endpoint in Late-Stage Trial 5/10/2017
Auris Med (EARS) Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study 5/9/2017
NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Delayed Decline In Several Health-Related Quality Of Life Scales Compared To Temozolomide Alone For Newly Diagnosed Glioblastoma Patients 5/8/2017
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS) 5/8/2017
Teva (TEVA), Active Biotech (BTPC) Suffer Another Setback After Laquinimod Flunks MS Study 5/8/2017
Faron Pharmaceuticals Ltd. Release: Update On Interest Phase III Study For Traumakine In Ards From IDMC 5/8/2017
4 Biotechs That Could Explode Or Crash In May 5/5/2017
GlaxoSmithKline (GSK) Release: Relvar Ellipta Significantly Improved Asthma Control In Salford Lung Study Patients Compared With Their Usual Care 5/5/2017
European Society For Medical Oncology (ESMO) - Osimertinib Improves Symptoms In Advanced Lung Cancer Patients 5/5/2017